Dr. Paul Slowey

Paul Slowey, PhD

Salivary Diagnostics Pioneer | Biotech Innovator & Scientific Leader

USA | Canada | UK

LinkedIn

Professional Summary

Dr. Paul Slowey is a globally recognised pioneer in oral fluid-based diagnostics with over 40 years of experience in biotech leadership, innovation, and commercialisation. He is the founder and CEO of Oasis Diagnostics® Corporation and has successfully developed and patented numerous saliva-based technologies now used globally for diagnostics in neurology, oncology, and infectious disease. With a track record that spans executive leadership, international sales, product innovation, and regulatory success, Dr. Slowey has played a pivotal role in advancing point-of-care diagnostics and standardised non-invasive testing.

Professional Experience

RapidDx Inc.
Chief Science Officer
2020 – Present

  • Oversees scientific strategy and product innovation for salivary biomarker-based diagnostics for mTBI (concussion), Alzheimer’s, Parkinson’s, and other neurological conditions

Oasis Diagnostics® Corporation
Founder & CEO
2007 – Present

  • Developed and commercialised over a dozen proprietary saliva collection and testing technologies, including Versi•SAL®, DNA•SALâ„¢, and VerOFy®
  • Secured 14 issued patents and 12 pending
  • Leads all company strategy, operations, and commercial partnerships

Bamburgh Marrsh LLC
Managing Member
2002 – Present

  • Technology transfer and IP holding company associated with Oasis Diagnostics

Hema Diagnostic Systems LLC
Executive Vice President (Consultant)
2001 – 2008

  • Led global sales and strategic licensing, including HIV biomarker exclusivity and regulatory registrations in multiple markets

BioCurex, Inc. (Canada)
Chief Executive Officer

  • Managed operations of a publicly traded cancer diagnostics company
  • Licensed RECAFâ„¢ technology to Abbott Diagnostics

OraSure Technologies, Inc.
Director, International Sales

  • Established global distribution network
  • Launched world’s first oral fluid-based HIV rapid test

Saliva Diagnostic Systems (SDS)
Chief Operating Officer / VP Sales & Marketing

  • Increased sales 100%, reduced costs, and secured major licensing deals
  • Closed non-profitable overseas facility and streamlined operations

Incstar Corporation
Director, International Sales & Marketing

  • Managed $22M business across 80+ countries
  • Increased sales despite market decline

Education

  • PhD – University of Newcastle-Upon-Tyne, UK
  • Postdoctoral Fellow – University of Victoria (Canada); Memorial University of Newfoundland (Canada)
  • BSc (Hons) – Sheffield City Polytechnic, UK

Honours and Leadership Roles

  • Honorary Professor – Central South University, China
  • Co-Chair – Alzheimer’s Association Business Consortium
  • Editor – Clinical Therapeutics, Frontiers in Neurology, Viruses, MDPI, JBR Journal
  • Co-Founder – North American Saliva Symposium & Saliva Summit of India
  • NIH SBIR Reviewer

Key Awards

  • NIH CAP Program Award (2016)
  • Frost & Sullivan Innovation and Strategy Awards (2012–2013)
  • Vancouver Business Journal Innovation of the Year (2013)

Key Awards

  • World Health Organisation & United Nations Panels
  • American Association for Clinical Chemistry
  • International Molecular Diagnostics Conferences
  • Asia-Pacific Saliva Symposiums
  • SalivaDirect Conference (Chicago 2023)

Full list available on request

Selected Publications and Book Chapters

  • COVID-19 Detection Strategies – Swab to Saliva (2022)
  • Contributor to over 10 peer-reviewed book chapters and 50+ academic articles
  • Editorial contributor to international journals on salivary diagnostics and biomarkers

Comprehensive publication list available on request

Pin It on Pinterest

Share This